Search results for "STIMULATION"

showing 10 items of 2192 documents

m-Chlorophenylpiperazine excites non-dopaminergic neurons in the rat Substantia Nigra and Ventral Tegmental Area by activating serotonin-2c receptors

2001

In vivo electrophysiological techniques were used to study the effect of m-chlorophenylpiperazine, a non-selective serotonin-2C receptor agonist, on the activity of non-dopaminergic neurons in the substantia nigra pars reticulata and the ventral tegmental area of anesthetized rats. Intravenous administration of m-chlorophenylpiperazine (5–320 μg/kg) caused a dose-dependent increase in the basal firing rate of a subpopulation of nigral neurons which do not respond to a footpinch stimulus [P(0) neurons], whereas it did not affect the activity of neurons which are responsive to the footpinch [P(+) neurons]. However, m-chlorophenylpiperazine (5–320 μg/kg) excited all non-dopaminergic neurons sa…

AgonistMalemedicine.medical_specialtyIndolesInterneuronmedicine.drug_classAminopyridinesSubstantia nigraStimulationPiperazinesRats Sprague-Dawleychemistry.chemical_compoundInternal medicinemedicineReceptor Serotonin 5-HT2CAnimals5-HT receptorgamma-Aminobutyric AcidNeuronsGABAergic neuronsChemistryGeneral NeuroscienceVentral Tegmental AreaRatsSerotonin Receptor AgonistsVentral tegmental areaSubstantia NigraElectrophysiologymedicine.anatomical_structureEndocrinologynervous systemReceptors SerotoninZona reticularisSerotoninSerotonin AntagonistsSB-242084Ventral tegmental area
researchProduct

Modulation by 5-HT3 and 5-HT4 receptors of the release of 5-hydroxytryptamine from the guinea-pig small intestine.

1993

The effects of agonists and antagonists of 5-hydroxytryptamine (5-HT) receptors on the release of endogenous 5-HT from enterochromaffin cells were studied in the vascularly perfused isolated guinea-pig small intestine. The experiments were done in the presence of tetrodotoxin in order to exclude a neuronally mediated influence on 5-HT release. The 5-HT3 receptor agonist 2-methyl-5-HT increased 5-HT release, and this effect was antagonized by 1 nmol/l tropisetron. Nanomolar concentrations of tropisetron, MDL 72,222 and granisetron decreased 5-HT release. Ondansetron (0.1 and 1 mumol/l) did not modify 5-HT release. 5-Methoxytryptamine, BIMU8 and cisapride concentration-dependently inhibited 5…

AgonistMalemedicine.medical_specialtySerotoninmedicine.drug_classGuinea PigsStimulationTetrodotoxinBiologychemistry.chemical_compoundInternal medicineIntestine SmallmedicineEnterochromaffin CellsAnimalsIntestinal MucosaReceptorPharmacologyGeneral Medicinemusculoskeletal systemSerotonin Receptor AgonistsPerfusionEndocrinologychemistryMetitepineReceptors SerotoninAutoreceptorEnterochromaffin cellTropisetronFemaleSerotoninSerotonin Antagonistsmedicine.drugNaunyn-Schmiedeberg's archives of pharmacology
researchProduct

Tachykinin NK(2) receptors facilitate acetylcholine release from guinea-pig isolated trachea.

2000

The release of newly synthesised [3H]acetylcholine was evoked by electrical field stimulation (5 Hz, 600 pulses) of epithelium-deprived guinea-pig trachea strips after sensory neuropeptides depletion with 3 microM capsaicin. The selective tachykinin NK(2) receptor agonist [betaAla(8)]neurokinin A-(4-10) increased in a concentration-dependent manner the electrically-induced release of [3H]acetylcholine. The facilitatory effect was antagonised by the selective non-peptide tachykinin NK(2) receptor antagonist, SR 48968 (apparent pK(B) 8.9). The tachykinin NK(1) and NK(3) receptor agonists substance P methyl ester and senktide (both 10 and 100 nM), respectively, did not affect the evoked releas…

AgonistMalemedicine.medical_specialtymedicine.drug_classNeurokinin AGuinea PigsSubstance PIn Vitro TechniquesCholinechemistry.chemical_compoundPiperidinesInternal medicinemedicineAnimalsReceptorPharmacologyNeuronsReceptors Neurokinin-2Receptor antagonistAcetylcholineElectric StimulationPeptide FragmentsTracheaEndocrinologychemistryCapsaicinBenzamidesNeurokinin ACapsaicinTachykinin receptorAcetylcholinemedicine.drugEuropean journal of pharmacology
researchProduct

Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF r…

2006

No specific treatment is available for ovarian hyperstimulation syndrome (OHSS), the most important complication in infertile women treated with gonadotropins. OHSS is caused by increased vascular permeability (VP) through ovarian hypersecretion of vascular endothelial growth factor (VEGF)activating VEGF receptor 2 (VEGFR-2). We previously demonstrated in an OHSS rodent model that increased VP was prevented by inactivating VEGFR-2 with a receptor antagonist(SU5416).However,duetoitstoxicity(thromboembolism) and disruption of VEGFR-2-dependent angiogenic processes critical for pregnancy, this kind of compound cannot be used clinically to prevent OHSS. Dopamine receptor 2 (Dp-r2) agonists, use…

AgonistVascular Endothelial Growth Factor Amedicine.medical_specialtyCabergolinemedicine.drug_classAngiogenesisOvarian hyperstimulation syndromeNeovascularization PhysiologicBiologyDopamine agonistCapillary Permeabilitychemistry.chemical_compoundOvarian Hyperstimulation SyndromeEndocrinologyCorpus LuteumInternal medicineCabergolinemedicineAnimalsRNA MessengerErgolinesPhosphorylationRats WistarReceptors Dopamine D2Kinase insert domain receptorReceptor antagonistmedicine.diseaseVascular Endothelial Growth Factor Receptor-2RatsVascular endothelial growth factorDisease Models AnimalEndocrinologychemistryDopamine AgonistsFemalemedicine.drugEndocrinology
researchProduct

Modulation by fenoldopam (SKF 82526) and bromocriptine of the electrically evoked release of vasopressin from the rat neurohypophysis. Effects of dop…

1986

1. Single neurointermediate lobes were fixed by their stalks to a platinum wire electrode and incubated in Krebs-bicarbonate solution. Vasopressin release into the medium was determined by a radioimmunoassay. Vasopressin secretion was increased by electrical stimulation (15 Hz, 10 s trains with 10 s intervals for 10 min). 2. Fenoldopam (SKF 82526) had a dual effect on vasopressin release, 30 nM decreasing (by 30%) and 3 μM increasing (by 32%) the evoked vasopressin secretion. The facilitatory effect of fenoldopam was antagonized in a concentration-dependent manner by flupenthixol but not by sulpiride. Sulpiride (1 μM) prevented the inhibitory effect of fenoldopam (30 μM). 3. After pretreatm…

AgonistVasopressinmedicine.medical_specialtyFenoldopammedicine.drug_classVasopressinsDopamineStimulationFenoldopamIn Vitro TechniquesReceptors DopaminePituitary Gland PosteriorDopamineInternal medicinemedicineAnimalsBromocriptinePharmacologyChemistryRats Inbred StrainsGeneral MedicineBenzazepinesBromocriptineElectric StimulationRatsEndocrinologyVasopressin secretionFemaleSulpiridemedicine.drugNaunyn-Schmiedeberg's archives of pharmacology
researchProduct

GnRH Analogues in the Prevention of Ovarian Hyperstimulation Syndrome

2012

The GnRH analogue (agonist and antagonist GnRH) changed ovarian stimulation. On the one hand, it improved chances of pregnancy to obtain more oocytes and better embryos. This leads to an ovarian hyper-response, which can be complicated by the ovarian hyperstimulation syndrome (OHSS). On the other hand, the GnRH analogue can prevent the incidence of OHSS: GnRH antagonist protocols, GnRH agonist for triggering final oocyte maturation, either together or separately, coasting, and the GnRH analogue may prove useful for avoiding OHSS in high-risk patients. We review these topics in this article.

Agonistendocrine systemmedicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and MetabolismOvarian hyperstimulation syndromeStimulationReview ArticleAndrologyOvarian Hyperstimulation SyndromeInternal medicinemedicineGnRH AntagonistPregnancyGnRH Agonistbusiness.industryPreventionGnRH AntagonistOocytemedicine.diseaseOvarian Stimulationmedicine.anatomical_structureEndocrinologyDisease preventionbusinesshormones hormone substitutes and hormone antagonistsInternational Journal of Endocrinology and Metabolism
researchProduct

Is ovarian stimulation detrimental to the endometrium?

2007

Ovarian stimulation in assisted reproduction technology produces lower implantation rates per embryo transferred than natural and ovum donation cycles, suggesting suboptimal endometrial development due to the abnormal concentrations of hormones used to recruit more oocytes. After the publication of several studies on the gene expression profile of endometrial receptivity in the natural cycle using microarray technology, researchers have investigated the impact of ovarian stimulation on the gene expression pattern of the endometrium. Ovarian stimulation cycles that use gonadotrophin-releasing hormone (GnRH) agonists and antagonists have been analysed in detail during the window of implantati…

Agonistendocrine systemmedicine.medical_specialtymedicine.drug_classStimulationBiologyEndometriumEndometriumOvulation InductionInternal medicineGene expressionmedicineHumansGeneUterine DiseasesObstetrics and GynecologyEmbryoGenomicsmedicine.anatomical_structureEndocrinologyReproductive MedicineGene Expression RegulationGene chip analysisFemaleDevelopmental BiologyHormoneReproductive biomedicine online
researchProduct

Subtype-Specific Desensitization of Human Endothelin ETA and ETB Receptors Reflects Differential Receptor Phosphorylation

1997

Endothelins regulate blood pressure in mammals through G protein-coupled receptors. Two receptor subtypes, ETA and ETB, exist which differ by their agonist profiles. Here we show subtype-specific differences in the inactivation of these endothelin receptors. Using a modified inositol phosphate accumulation assay, we found that stimulation of ETA by endothelin-1 results in sustained activation of the subtype, retaining >30% of its initial activity even 20 min after agonist administration, whereas the ETB rapidly deactivated after agonist stimulation, losing >80% of its initial activity within 5 min after endothelin application. The discrepancy in receptor inactivation is reflected by subtype…

Agonistmedicine.hormonemedicine.medical_specialtyEndothelin receptor type Amedicine.drug_classmedia_common.quotation_subjectStimulationCHO CellsPalmitic AcidsSpodopteraLigandsBiochemistryEndothelinsCricetinaeInternal medicinemedicineAnimalsHumansPhosphorylationInternalizationReceptorProtein Kinase Cmedia_commonReceptors EndothelinChemistryImmune Serarespiratory systemReceptor Endothelin AReceptor Endothelin BKineticsEndocrinologycardiovascular systemPhosphorylationEndothelin receptorcirculatory and respiratory physiologyBiochemistry
researchProduct

ATP and endogenous agonists inhibit evoked [3H]-noradrenaline release in rat iris via A1 and P2y-like purinoceptors.

1993

Effects of ATP, adenosine and purinoceptor antagonists on field stimulation-evoked (3 Hz, 2 min) [3H]-noradrenaline overflow were investigated in the rat isolated iris. ATP and adenosine inhibited the evoked overflow of [3H]-noradrenaline. 1,3-Dipropyl-8-cyclopentylxanthine (DPCPX) shifted the concentration-response curve of ATP to the right in a concentration-dependent manner, but with a potency (-log KB = 7.88) much lower than expected for an A1 adenosine receptor. In the continuous presence of DPCPX, the ATP-induced prejunctional inhibition was unaffected by suramin (100 mumol/l) and DIDS (4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid, 50 mumol/l) but was antagonized by the P2Y-rece…

Agonistmedicine.medical_specialtyAdenosinemedicine.drug_classSuraminIrisSuraminBiologyP2 receptor44'-Diisothiocyanostilbene-22'-Disulfonic AcidIn Vitro TechniquesSynaptic Transmissionchemistry.chemical_compoundNorepinephrineAdenosine TriphosphateInternal medicinemedicinePurinergic P2 Receptor AntagonistsAnimalsRats WistarPharmacologyProtein Synthesis InhibitorsReceptors Purinergic P2TriazinesPurinergic receptorReceptors Purinergic P1General MedicineAdenosine receptorAdenosineElectric StimulationRatsEndocrinologychemistryPurinergic P1 Receptor AntagonistsDIDSXanthinesAutoreceptormedicine.drugNaunyn-Schmiedeberg's archives of pharmacology
researchProduct

Induction of Apoptosis in Rat Cardiocytes by A3 Adenosine Receptor Activation and Its Suppression by Isoproterenol

2000

The purpose of the present study was to investigate the mechanisms involved in the induction of apoptosis in newborn cultured cardiomyocytes by activation of adenosine (ADO) A3 receptors and to examine the protective effects of beta-adrenoceptors. The selective agonist for A3 ADO receptors Cl-IB-MECA (2-chloro-N6-iodobenzyl-5-N-methylcarboxamidoadenosine) and the antagonist MRS1523 (5-propyl-2-ethyl-4-propyl-3-(ethylsulfanylcarbonyl)-6-phenylpy rid ine-5-carboxylate) were used. High concentrations of the Cl-IB-MECA (or = 10 microM) agonist induced morphological modifications of myogenic cells, such as rounding and retraction of cell body and dissolution of contractile filaments, followed by…

Agonistmedicine.medical_specialtyProgrammed cell deathAdenosineCardiotonic Agentsmedicine.drug_classApoptosisStimulationBiologyInternal medicinePurinergic P1 Receptor AgonistsmedicineAnimalsProtein kinase AReceptorCells CulturedMyocardiumReceptor Adenosine A3IsoproterenolReceptors Purinergic P1HeartCell BiologyAdenosineAdenosine receptorRatsCell biologyEndocrinologyApoptosisSignal Transductionmedicine.drugExperimental Cell Research
researchProduct